CD20-TCB can redirect the activity of conventional CD4 and CD8 T cells against lymphoma cells by concomitant binding of CD20 on tumor cells and CD3 on T cells (S1b Fig) [7,10]. This evidence concerns the gene CD8A and neoplasm.